LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 (neratinib) were presented at the 2017 American Association for Cancer Research Annual Meeting (AACR) that is currently taking place in Washington, D.C. The presentation entitled, Neratinib in HER2 or HER3 mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 basket study, was presented as a plenary session by David Hyman, M.D., Director of Developmental Therapeutics at Memorial Sloan Kettering Cancer Center (MSK), and principal investigator of the trial.
The Phase II SUMMIT basket trial is an open-label, multicenter, multinational study to evaluate the safety and efficacy of PB272 administered daily to patients who have solid tumors with activating HER2 or HER3 mutations. All patients received loperamide (16 mg per day initially) prophylactically for the first cycle of treatment in order to reduce the neratinib-related diarrhea.
Included in the presentation were data on 141 patients enrolled in the neratinib monotherapy arm of the trial, including 124 patients with HER2 mutations and 17 patients with HER3 mutations. This included patients with 21 unique tumor types, with the most common being breast, lung, bladder and colorectal cancer. There were also 30 distinct HER2 and 12 distinct HER3 mutations observed among these patients, with the most frequent HER2 variants involving S310, L755, A755_G776insYVMA and V777.
In the HER2-mutant cohort, clinical responses were observed in tumors with S310, L755, V777, P780_Y781insGSP and A775_G776insYVMA mutations. When stratified by tumor type, responses were observed in patients with breast, cervical, biliary, salivary and non-small-cell lung cancers, which led to cohort expansions in these tumor types. No activity was observed in the HER3-mutant cohort. A more detailed presentation of the data is presented in Table 1 below and a copy of the full presentation is available on the Puma Biotechnology website.
HER2mut
HER2mut
HER2mut
HER2mut
HER2mut
HER2mut
HER3mut
Lung
(95% CI)
rate, n (%)
(95% CI)
20.1
(95% CI)
(0.5--NA)
The neratinib safety profile observed in the SUMMIT study is consistent with that observed previously in metastatic patients with HER2 amplified tumors. With anti-diarrheal prophylaxis and management, diarrhea was not a treatment-limiting side effect in SUMMIT. The interim safety results of the study showed that the most frequently observed adverse event was diarrhea. For the 141 patients enrolled in the neratinib monotherapy arm with safety data available, 31 patients (22%) reported grade 3 diarrhea. The median duration of grade 3 diarrhea for those patients was 2 days. 4 patients (2.8%) permanently discontinued neratinib due to diarrhea and 21 patients (14.9%) temporarily discontinued neratinib due to diarrhea and then restarted after the diarrhea subsided.
Dr. David Hyman stated, "Neratinib showed signs of clinical activity in several of the cohorts in the SUMMIT trial. The safety profile of the drug was manageable and the diarrhea was not treatment-limiting with appropriate prophylaxis and management. We look forward to completing enrollment in the ongoing cohorts in the study and continuing to utilize the basket trial design to explore possible treatment options for these select patient populations.
"The basket-trial design we are utilizing for SUMMIT is enabling us to evaluate the clinical potential of neratinib in patients with specific mutation-types rather than limiting exploration to one tumor type at a time. It is an efficient approach that is generating clinically meaningful information to guide targeted therapy across a broad spectrum of tumor types with HER mutations, including in patients with rare tumors who may not otherwise have access to investigational therapies, said Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology. We are very pleased with the preliminary activity seen with neratinib in the SUMMIT trial. We look forward to advancing this targeted compound into further clinical development in multiple HER2 mutant tumor types, both as monotherapy and in novel combinations."
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The Company in-licenses the global development and commercialization rights to three drug candidatesPB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Currently, the Company is primarily focused on the development of the oral version of neratinib, and its most advanced drug candidates are directed at the treatment of HER2-positive breast cancer. The Company believes that neratinib has clinical application in the treatment of several other cancers as well, including non-small cell lung cancer and other tumor types that over-express or have a mutation in HER2. Further information about Puma Biotechnology can be found at http://www.pumabiotechnology.com.
Forward-Looking Statements:
This press release contains forward-looking statements, including statements regarding the development of the Companys drug candidates. All forward-looking statements included in this press release involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the fact that the Company has no product revenue and no products approved for marketing; the Company's dependence on PB272, which is still under development and may never receive regulatory approval; the challenges associated with conducting and enrolling clinical trials; the risk that the results of clinical trials may not support the Company's drug candidate claims; even if approved, the risk that physicians and patients may not accept or use the Company's products; the Company's reliance on third parties to conduct its clinical trials and to formulate and manufacture its drug candidates; the Company's dependence on licensed intellectual property; and the other risk factors disclosed in the periodic and current reports filed by the Company with the Securities and Exchange Commission from time to time, including the Company's Annual Report on Form 10-K for the year ended December 31, 2016. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.
- Angel Biotechnology (ABH) - Video [Last Updated On: November 28th, 2011] [Originally Added On: November 28th, 2011]
- Curing the entire world through biotechnology [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Biotechnological innovation on Farming Skill [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Growth and development of Biotechnology [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Biotechnology: Boon to Human being [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Philippines banks on biotechnology to deal with enviromentally friendly issues, food security considerations [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Philippines banks on biotechnology to deal with enviromentally friendly issues, food security considerations [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Biotechnology: Boon to Human being [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Growth and development of Biotechnology [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Biotechnological innovation on Farming Skill [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Curing the entire world through biotechnology [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Scientists make ethical stem cells from skin of a rat [Last Updated On: January 22nd, 2012] [Originally Added On: January 22nd, 2012]
- India emerging as a global hub for stem cell research [Last Updated On: January 22nd, 2012] [Originally Added On: January 22nd, 2012]
- India emerging as a global hub for stem cell research [Last Updated On: January 22nd, 2012] [Originally Added On: January 22nd, 2012]
- Scientists make ethical stem cells from skin of a rat [Last Updated On: January 22nd, 2012] [Originally Added On: January 22nd, 2012]
- Alzheimer Disease - New Drugs, Markets and Companies [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- Amazing Stem Cell Therapy Results | Before [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- Stemcell therapy for pets - Mi Mascota - Video [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- Stem cells for dogs? New pain management therapy works for pets - Video [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- Riot's Lameness Moving Exam Pre Stem Cell Therapy - Video [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- Riot's Lameness Palpation Exam Pre Stem Cell Therapy - Video [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- Ariel's Stem Cell Miracle! - Video [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- South Korea again gives a go ahead to use of human eggs in cloning research [Last Updated On: February 5th, 2012] [Originally Added On: February 5th, 2012]
- South Korea again gives a go ahead to use of human eggs in cloning research [Last Updated On: February 5th, 2012] [Originally Added On: February 5th, 2012]
- Angel Biotechnology - Contracts with Materia Medica [Last Updated On: February 7th, 2012] [Originally Added On: February 7th, 2012]
- Cellerant Therapeutics Appoints Lowell E. Sears to Board of Directors [Last Updated On: February 21st, 2012] [Originally Added On: February 21st, 2012]
- Angel Biotechnology - Grant of Share Options [Last Updated On: February 27th, 2012] [Originally Added On: February 27th, 2012]
- RBCC Closes Deal with Game Changing Biotech Firm [Last Updated On: March 16th, 2012] [Originally Added On: March 16th, 2012]
- The year of the dragon looks auspicious for Australian Biotechnology [Last Updated On: March 25th, 2012] [Originally Added On: March 25th, 2012]
- The year of the dragon looks auspicious for Australian Biotechnology [Last Updated On: March 25th, 2012] [Originally Added On: March 25th, 2012]
- David Allan Lauded for Leadership – Biotechnology Leader Named to Industry Award [Last Updated On: May 9th, 2012] [Originally Added On: May 9th, 2012]
- Angel Biotechnology - Angel signs new contract with ReNeuron [Last Updated On: May 17th, 2012] [Originally Added On: May 17th, 2012]
- MYOS Names Veteran Biotechnology Executive Dr. Sol J. Barer to Chair Scientific Advisory Board [Last Updated On: June 27th, 2012] [Originally Added On: June 27th, 2012]
- StemCells and Keryx Biopharmaceuticals Showing Strong Gains as Biotechnology Industry Soars in 2012 [Last Updated On: July 24th, 2012] [Originally Added On: July 24th, 2012]
- Osiris Therapeutics and Pluristem Therapeutics Showing Impressive Growth as Biotech Industry Thrives in 2012 [Last Updated On: August 4th, 2012] [Originally Added On: August 4th, 2012]
- Allele Biotechnology Announces New Advance in Production of Human Stem Cells [Last Updated On: September 14th, 2012] [Originally Added On: September 14th, 2012]
- BIO Announces Therapeutic Workshops for 11th Annual BIO Investor Forum [Last Updated On: September 25th, 2012] [Originally Added On: September 25th, 2012]
- Biotech Industry Applauds Introduction of the High Technology Small Business Research Incentives Act [Last Updated On: October 2nd, 2012] [Originally Added On: October 2nd, 2012]
- Biotech Industry Look to Benefit From New Act Designed to Promote R&D Joint Ventures [Last Updated On: October 15th, 2012] [Originally Added On: October 15th, 2012]
- David Lichtenstein: Biotechnology is Rich Area for Investment [Last Updated On: November 2nd, 2012] [Originally Added On: November 2nd, 2012]
- Donna Dickenson introduces Bioethics - Video [Last Updated On: November 2nd, 2012] [Originally Added On: November 2nd, 2012]
- Coare Biotechnology and ChemDiv Establish Co-Marketing and Service Collaboration [Last Updated On: November 9th, 2012] [Originally Added On: November 9th, 2012]
- blood banks | Umbilical Cord Blood Banking Could Be an Investment in Our Future Health - Video [Last Updated On: November 12th, 2012] [Originally Added On: November 12th, 2012]
- Research and Markets: Research Report on the Biotechnology Market in India 2012 [Last Updated On: November 18th, 2012] [Originally Added On: November 18th, 2012]
- Life Un(Ltd), Charis Thompson, Three Times a Woman- A Gendered Economy of Stem Cell Innovation Pt. 2 - Video [Last Updated On: November 30th, 2012] [Originally Added On: November 30th, 2012]
- Life UnLtd, Charis Thompson, Three Times a Woman A Gendered Economy of Stem Cell Innovation Pt 1 - Video [Last Updated On: November 30th, 2012] [Originally Added On: November 30th, 2012]
- Biotechnology: Things you should know about Gene Therapy [Last Updated On: December 2nd, 2012] [Originally Added On: December 2nd, 2012]
- Biotechnology: Things you should know about Gene Therapy [Last Updated On: December 2nd, 2012] [Originally Added On: December 2nd, 2012]
- Top trends for Biotechnology [Last Updated On: December 9th, 2012] [Originally Added On: December 9th, 2012]
- Top trends for Biotechnology [Last Updated On: December 9th, 2012] [Originally Added On: December 9th, 2012]
- Angel Biotechnology losses widen [Last Updated On: December 10th, 2012] [Originally Added On: December 10th, 2012]
- Why Biotech ETFs are a Top Sector in 2012 [Last Updated On: December 19th, 2012] [Originally Added On: December 19th, 2012]
- Things to know about the real fountain of youth [Last Updated On: January 11th, 2013] [Originally Added On: January 11th, 2013]
- Things to know about the real fountain of youth [Last Updated On: January 20th, 2013] [Originally Added On: January 20th, 2013]
- DNA testing is Good or Bad: Let’s Discuss [Last Updated On: March 2nd, 2013] [Originally Added On: March 2nd, 2013]
- Computer Review Announces New Tools to Deal with the Flood of Information from the Biotechnology Sector [Last Updated On: March 7th, 2013] [Originally Added On: March 7th, 2013]
- DNA testing is Good or Bad: Let’s Discuss [Last Updated On: March 10th, 2013] [Originally Added On: March 10th, 2013]
- The Mystery about Cyanide Taste [Last Updated On: March 31st, 2013] [Originally Added On: March 31st, 2013]
- The Mystery about Cyanide Taste [Last Updated On: April 14th, 2013] [Originally Added On: April 14th, 2013]
- Are Biodegradable Heart Stents Safe? [Last Updated On: April 17th, 2013] [Originally Added On: April 17th, 2013]
- Piper Jaffray Biotechnology Analyst Participates in Historical Medical Event at the Vatican [Last Updated On: April 17th, 2013] [Originally Added On: April 17th, 2013]
- Are Biodegradable Heart Stents Safe? [Last Updated On: April 21st, 2013] [Originally Added On: April 21st, 2013]
- TaiGen Biotechnology Announces Submission of New Drug Application for Nemonoxacin in Taiwan and Mainland China [Last Updated On: May 17th, 2013] [Originally Added On: May 17th, 2013]
- How good to use home pregnancy tests [Last Updated On: June 1st, 2013] [Originally Added On: June 1st, 2013]
- How good to use home pregnancy tests [Last Updated On: June 2nd, 2013] [Originally Added On: June 2nd, 2013]
- Questions you should ask to doctor for Alzheimer disease [Last Updated On: July 6th, 2013] [Originally Added On: July 6th, 2013]
- Questions you should ask to doctor for Alzheimer disease [Last Updated On: July 7th, 2013] [Originally Added On: July 7th, 2013]
- BetaStem Therapeutics Retains Conditas Biotechnology Group for Business Development and Corporate Strategy [Last Updated On: July 18th, 2013] [Originally Added On: July 18th, 2013]
- Sanguine BioSciences Announces Distribution Partnership with AMS Biotechnology [Last Updated On: August 8th, 2013] [Originally Added On: August 8th, 2013]
- Matric Revision: Life Sciences: Genetics: Biotechnology (5/9): Cloning (1/4) - Video [Last Updated On: October 27th, 2013] [Originally Added On: October 27th, 2013]
- Matric Revision: Life Sciences: Genetics: Biotechnology (6/9): Cloning (2/4) - Video [Last Updated On: October 29th, 2013] [Originally Added On: October 29th, 2013]
- History of biotechnology - Wikipedia, the free encyclopedia [Last Updated On: December 16th, 2013] [Originally Added On: December 16th, 2013]
- Exciting business ideas in biotechnology and healthcare - Video [Last Updated On: February 19th, 2014] [Originally Added On: February 19th, 2014]
- Crippled canines get new leash on life [Last Updated On: March 27th, 2014] [Originally Added On: March 27th, 2014]
- Stem Cell Treatment for Dogs - pet insurance [Last Updated On: March 27th, 2014] [Originally Added On: March 27th, 2014]
- New patenting guidelines needed for biotechnology, experts argue [Last Updated On: April 24th, 2014] [Originally Added On: April 24th, 2014]
- New tumor-targeting agent images and treats wide variety of cancers [Last Updated On: June 24th, 2014] [Originally Added On: June 24th, 2014]
- San Diego Hosts World's Largest Biotechnology Convention - Video [Last Updated On: June 28th, 2014] [Originally Added On: June 28th, 2014]
- Shot in the arm for research on disease biology [Last Updated On: July 13th, 2014] [Originally Added On: July 13th, 2014]
- biotechnology -- Encyclopedia Britannica [Last Updated On: August 28th, 2014] [Originally Added On: August 28th, 2014]